No significant difference existed in serum EGFR mRNA levels between ADC and SCC either at baseline [median (min, max), 16.0 (1.9, 66.7) and 16.9 (4.1, 42.8) respectively, p=0.84], or after treatment [median (min, max), 9.2 (3.4, 56.5) and 9.3 (2.5, 41.8) respectively, p=0.76] or between subjects with metastatic disease and non-metastatic disease. Here, EGFR is linked to metastatic neoplasm.